Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer

Despite their falling stock prices, both of these companies have solid prospects. Pfizer has been busy making deals -- something that is already paying off.

2 High-Yield Dividend Stocks to Buy on the Dip

Gilead Sciences has experienced a boom-bust-recovery cycle, with its fortunes changing after acquiring Pharmasset and obtaining a cure for HCV. Revenues have been stagnant for nearly a decade, with the company relying heavily on its HIV franchise today. The second quarter earnings report showed mixed results, with non-Veklury sales growing solidly but a slight pullback in earnings guidance was seen.

Gilead Sciences: Mixed Signals, Again

Gilead's (GILD) Q2 earnings miss on litigation charges while revenues beat on strong oncology and HIV franchise.

Gilead's (GILD) Q2 Earnings Miss, Revenues Beat on Oncology

With a daily gain of 4.63% and an Earnings Per Share (EPS) of 4.43, Gilead Sciences Inc ( GILD , Financial) has been attracting attention in the investment community. This article aims to answer the pressing question: is Gilead Sciences (GILD) fairly valued?

Is Gilead Sciences (GILD) Fairly Valued? An In-Depth Analysis

Gilead Sciences, Inc. (NASDAQ:GILD ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Cindy Perettie - Executive Vice President, Kite Conference Call Participants Geoff Meacham - Bank of America Chris Schott - JPMorgan Tyler Van Buren - TD Cowen Terrence Flynn - Morgan Stanley Bill Jahangiri - Truist Brian Abrahams - RBC Capital Markets Carter Gould - Barclays Matthew Dellatorre - Goldman Sachs Colin Bristow - UBS Evan Seigerman - BMO Capital Markets Joseph Catanzaro - Piper Sandler Mohit Bansal - Wells Fargo Simon Baker - Redburn Operator Hello, everyone. Thank you for attending Gilead Sciences' Second Quarter 2023 Earnings Conference Call.

Gilead Sciences, Inc. (GILD) Q2 2023 Earnings Call Transcript

The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Gilead (GILD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Gilead Sciences (GILD) came out with quarterly earnings of $1.34 per share, missing the Zacks Consensus Estimate of $1.60 per share. This compares to earnings of $1.58 per share a year ago.

Gilead Sciences (GILD) Q2 Earnings Lag Estimates

Two of Gilead's cancer drugs topped second-quarter sales expectations Thursday. But GILD stock could be hamstrung on an earnings miss.

Will An Earnings Miss Cloud Gilead's Massive Cancer Treatment Growth?

Gilead Sciences Inc.'s stock GILD, -0.20% slid 2% in after-hours trade Thursday, after the drug company posted weaker-than-expected second-quarter profit and lowered its guidance. Foster City, Calif.

Gilead's stock slides 2% after Q2 profit lags consensus and as company lowers guidance

Gilead Sciences on Thursday reported lower second-quarter profit as costs from a legal settlement and sharply lower sales of its COVID-19 treatment offset another strong performance by HIV drugs.

Gilead quarterly profit falls on COVID sales drop, legal settlement charge

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter of 2023. “It was another strong quarter for Gilead, with continued commercial and clinical momentum,” said Daniel O'Day, Gilead's Chairman and Chief Executive Officer. “11% year-over-year growth across our base business was driven by our diverse portfolio of therapies for HIV, Oncology, and Liver Disease. We received positive regulatory updates for six of o.

Gilead Sciences Announces Second Quarter 2023 Financial Results

Biogen

Regeneron Pharmaceuticals

The biotechnology sector is huge and growing. Grand View Research forecasts that the industry will reach $3.88 trillion by 2030, growing at a compound annual growth rate of 14%.

Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its second-quarter 2023 results.

Gilead (GILD) Gears Up to Report Q2 Earnings: What's in Store?

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) approved Trodelvy® (sacituzumab govitecan) as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting. The approval by the European Commission follows the positive opinion of.

European Commission Approves Gilead's Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today presented new data reinforcing the efficacy, safety, and tolerability profile of lenacapavir, including patient-reported outcomes (PRO) from the Phase 2/3 CAPELLA trial. These latest findings underscore the role of lenacapavir, the first long-acting injectable HIV treatment medication administered twice-yearly, as a person-centric therapy option and its transformative potential impact on the future of coordinated H.

Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV

Gilead Sciences, Inc. (GILD) discontinues phase III ENHANCE study, evaluating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes, due to futility based on a planned analysis.

Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab

Gilead Sciences, Inc. (NASDAQ:GILD) started on the back foot on Monday after the biopharmaceutical company told investors it has discontinued its Phase 3 ENHANCE study of its investigational anti-CD47 antibody magrolimab for the treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS). Foster City, California-based Gilead said in a statement the decision to end the study was due to “futility based on a planned analysis.

Gilead Sciences shares decline after it discontinues blood cancer treatment trial

Cognizant Technology Solutions

Cognizant will manage Gilead's global IT infrastructure while leading digital transformation initiatives designed to enhance overall client experience and enable faster time to market for Gilead products. TEANECK, N.J.

Cognizant and Gilead Extend Partnership with Five-Year Service Agreement Estimated at $800 Million

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from multiple studies reinforcing Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a treatment option for a broad range of people with HIV. The latest findings include key insights into the treatment of virologically suppressed pregnant women and children two years of age or older (weighing at least 14 kg to less than 25 kg) and positive Week 96 da.

New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences Inc. (Nasdaq: GILD) today announced its largest commitment to health equity for Australian and Canadian Indigenous communities. The initiative will support programs addressing societal barriers to care that persistently contribute to the transmission of HIV and viral hepatitis within Indigenous communities. Gilead is in discussions with two Indigenous-led organizations, the Lowitja Institute in Australia and CAAN Communities, Alliances &.

Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities

Shares of Gilead Sciences Inc. GILD, +0.88% dropped nearly 2% in the extended session Friday after the pharma company said it has ended a late-stage trial of a treatment for a rare type of blood cancer after an analysis. “The health and well-being of patients are our top priorities and while this is disappointing news it confirms the challenges of treating [higher-risk myelodysplastic syndromes,] where no new class of treatments have been approved in nearly 20 years,” Gilead's Chief Medical Officer Merdad Parsey said in a statement.

Gilead ends late-stage trial of blood cancer treatment

Gilead Sciences Inc said on Friday it was stopping a late-stage trial of its blood cancer treatment following an analysis.

Gilead stops late-stage trial of blood cancer treatment

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) has been discontinued due to futility based on a planned analysis. The safety data seen in this study is consistent with the known magrolimab profile and adverse events that are typical in this patient population. Gilead recommends discontinuing treatment with magrolimab in patients with MDS. Magrolimab is a potential first-in-c.

Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $8 million in funding through a new grant program in the United States called Gilead Relink, which is focused on bringing diagnosed but untreated people living with hepatitis C virus (HCV) or hepatitis B virus (HBV) back into care. The CDA Foundation (CDAF), based in Lafayette, Colorado, will act as the lead organization for the program and be responsible for implementing and ov.

Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.

LAFAYETTE, Colo.--(BUSINESS WIRE)--The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead's Relink grant program. CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care. Despite the availability of existing treatment and vacc.

Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant From Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States

News for Gilead Sciences Stock (GILD)